Kodiak Sciences Inc KOD

US Biotechnology

$32.35 ▼ -2.62% ($-0.87)

⬆️ Above Yest. High 🔥 High Short Interest 🎢 High Beta

Open $33.03

Prev Close $33.22

Day Range $31.00 – $33.71

52W Range $10.94 – $47.84

Market Cap $2.03B

Beta 2.20

EPS (TTM) $-4.19

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2018-10-04
Shares Out.	62,580,000
Website	kodiak.com/ ↗
Phone	13026365400
Employees	124
Revenue	$0
Gross Profit	$0
Net Income	-$65.6M
Free Cash Flow	-$159.9M
Total Assets	$256.8M
Total Liabilities	$195.7M
Equity	$61.1M

About Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Kodiak Sciences Inc is a publicly traded company under the ticker symbol KOD on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.